Lifecore Total Assets vs Total Liab Analysis

LFCR Stock

7.31 0.33 4.73%

Lifecore Biomedical financial indicator trend analysis is infinitely more than just investigating Lifecore Biomedical recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lifecore Biomedical is a good investment. Please check the relationship between Lifecore Biomedical Total Assets and its Total Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.

Total Assets vs Total Liab

Total Assets vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lifecore Biomedical Total Assets account and Total Liab. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Lifecore Biomedical's Total Assets and Total Liab is 0.85. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Total Liab in the same time period over historical financial statements of Lifecore Biomedical, assuming nothing else is changed. The correlation between historical values of Lifecore Biomedical's Total Assets and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Lifecore Biomedical are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Total Assets i.e., Lifecore Biomedical's Total Assets and Total Liab go up and down completely randomly.

Correlation Coefficient

0.85

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Total Assets

Total assets refers to the total amount of Lifecore Biomedical assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lifecore Biomedical books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Lifecore Biomedical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lifecore Biomedical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.At this time, Lifecore Biomedical's Selling General Administrative is relatively stable compared to the past year. As of 11/22/2024, Tax Provision is likely to grow to about 192.2 K, while Issuance Of Capital Stock is likely to drop 0.00.

	2021	2023	2024 (projected)
Total Revenue	185.8M	128.3M	121.8M
Interest Expense	17.4M	18.1M	19.0M

Total Revenue Interest Expense

Lifecore Biomedical fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Net Receivables	Intangible Assets	Common Stock	Current Deferred Revenue	Short Term Investments
Total Assets		0.7	0.61	0.89	0.79	0.88	0.65	0.53	0.75	-0.61	0.99	-0.73	-0.61	0.6	0.46	0.66	0.12	0.69	0.85	0.85	0.4	0.9	0.31	-0.66	-0.48	-0.72
Short Long Term Debt Total	0.7		0.7	0.79	0.17	0.87	0.97	-0.07	0.22	-0.77	0.58	-0.69	-0.77	0.54	0.72	0.95	0.51	0.8	0.95	0.91	0.66	0.53	-0.13	-0.39	-0.3	-0.32
Other Current Liab	0.61	0.7		0.5	0.28	0.63	0.67	0.1	0.0	-0.43	0.56	-0.65	-0.44	0.4	0.6	0.63	0.56	0.53	0.7	0.65	0.25	0.24	0.06	-0.39	-0.27	-0.4
Total Current Liabilities	0.89	0.79	0.5		0.59	0.84	0.77	0.38	0.7	-0.66	0.83	-0.7	-0.66	0.44	0.43	0.76	0.21	0.61	0.84	0.91	0.64	0.86	0.22	-0.49	-0.48	-0.58
Total Stockholder Equity	0.79	0.17	0.28	0.59		0.51	0.08	0.92	0.79	-0.28	0.86	-0.5	-0.31	0.27	-0.13	0.19	-0.09	0.27	0.38	0.46	0.13	0.78	0.58	-0.47	-0.41	-0.74
Property Plant And Equipment Net	0.88	0.87	0.63	0.84	0.51		0.84	0.21	0.5	-0.84	0.82	-0.67	-0.85	0.66	0.62	0.83	0.27	0.85	0.94	0.86	0.54	0.76	-0.11	-0.55	-0.29	-0.49
Net Debt	0.65	0.97	0.67	0.77	0.08	0.84		-0.2	0.2	-0.78	0.53	-0.63	-0.76	0.53	0.83	0.92	0.46	0.75	0.9	0.88	0.62	0.51	-0.26	-0.4	-0.27	-0.27
Retained Earnings	0.53	-0.07	0.1	0.38	0.92	0.21	-0.2		0.63	-0.06	0.62	-0.41	-0.1	-0.09	-0.47	-0.06	-0.05	-0.06	0.09	0.22	0.02	0.54	0.68	-0.15	-0.31	-0.56
Accounts Payable	0.75	0.22	0.0	0.7	0.79	0.5	0.2	0.63		-0.22	0.8	-0.38	-0.22	0.37	0.06	0.19	-0.37	0.3	0.43	0.48	0.18	0.89	0.51	-0.52	-0.44	-0.59
Cash	-0.61	-0.77	-0.43	-0.66	-0.28	-0.84	-0.78	-0.06	-0.22		-0.53	0.52	0.99	-0.38	-0.49	-0.8	-0.45	-0.69	-0.71	-0.74	-0.62	-0.56	0.4	0.25	0.04	0.26
Non Current Assets Total	0.99	0.58	0.56	0.83	0.86	0.82	0.53	0.62	0.8	-0.53		-0.71	-0.54	0.55	0.37	0.53	0.04	0.59	0.76	0.75	0.29	0.89	0.36	-0.64	-0.47	-0.72
Non Currrent Assets Other	-0.73	-0.69	-0.65	-0.7	-0.5	-0.67	-0.63	-0.41	-0.38	0.52	-0.71		0.54	-0.1	-0.4	-0.52	-0.45	-0.32	-0.71	-0.68	-0.28	-0.49	-0.17	0.1	0.3	0.25
Cash And Short Term Investments	-0.61	-0.77	-0.44	-0.66	-0.31	-0.85	-0.76	-0.1	-0.22	0.99	-0.54	0.54		-0.37	-0.45	-0.8	-0.47	-0.7	-0.72	-0.73	-0.63	-0.56	0.38	0.23	0.05	0.27
Common Stock Shares Outstanding	0.6	0.54	0.4	0.44	0.27	0.66	0.53	-0.09	0.37	-0.38	0.55	-0.1	-0.37		0.64	0.59	-0.15	0.9	0.68	0.56	0.25	0.58	0.0	-0.9	-0.34	-0.6
Non Current Liabilities Total	0.46	0.72	0.6	0.43	-0.13	0.62	0.83	-0.47	0.06	-0.49	0.37	-0.4	-0.45	0.64		0.64	0.2	0.67	0.72	0.58	0.21	0.27	-0.35	-0.49	-0.15	-0.11
Inventory	0.66	0.95	0.63	0.76	0.19	0.83	0.92	-0.06	0.19	-0.8	0.53	-0.52	-0.8	0.59	0.64		0.51	0.85	0.88	0.93	0.75	0.56	-0.11	-0.48	-0.34	-0.46
Other Current Assets	0.12	0.51	0.56	0.21	-0.09	0.27	0.46	-0.05	-0.37	-0.45	0.04	-0.45	-0.47	-0.15	0.2	0.51		0.17	0.33	0.41	0.58	-0.15	-0.16	0.23	0.08	0.05
Other Stockholder Equity	0.69	0.8	0.53	0.61	0.27	0.85	0.75	-0.06	0.3	-0.69	0.59	-0.32	-0.7	0.9	0.67	0.85	0.17		0.85	0.77	0.52	0.62	-0.13	-0.74	-0.31	-0.54
Total Liab	0.85	0.95	0.7	0.84	0.38	0.94	0.9	0.09	0.43	-0.71	0.76	-0.71	-0.72	0.68	0.72	0.88	0.33	0.85		0.91	0.55	0.68	0.03	-0.55	-0.36	-0.45
Total Current Assets	0.85	0.91	0.65	0.91	0.46	0.86	0.88	0.22	0.48	-0.74	0.75	-0.68	-0.73	0.56	0.58	0.93	0.41	0.77	0.91		0.69	0.76	0.15	-0.56	-0.47	-0.62
Short Term Debt	0.4	0.66	0.25	0.64	0.13	0.54	0.62	0.02	0.18	-0.62	0.29	-0.28	-0.63	0.25	0.21	0.75	0.58	0.52	0.55	0.69		0.43	-0.08	-0.22	-0.3	-0.34
Net Receivables	0.9	0.53	0.24	0.86	0.78	0.76	0.51	0.54	0.89	-0.56	0.89	-0.49	-0.56	0.58	0.27	0.56	-0.15	0.62	0.68	0.76	0.43		0.32	-0.68	-0.52	-0.75
Intangible Assets	0.31	-0.13	0.06	0.22	0.58	-0.11	-0.26	0.68	0.51	0.4	0.36	-0.17	0.38	0.0	-0.35	-0.11	-0.16	-0.13	0.03	0.15	-0.08	0.32		-0.23	-0.44	-0.5
Common Stock	-0.66	-0.39	-0.39	-0.49	-0.47	-0.55	-0.4	-0.15	-0.52	0.25	-0.64	0.1	0.23	-0.9	-0.49	-0.48	0.23	-0.74	-0.55	-0.56	-0.22	-0.68	-0.23		0.53	0.83
Current Deferred Revenue	-0.48	-0.3	-0.27	-0.48	-0.41	-0.29	-0.27	-0.31	-0.44	0.04	-0.47	0.3	0.05	-0.34	-0.15	-0.34	0.08	-0.31	-0.36	-0.47	-0.3	-0.52	-0.44	0.53		0.66
Short Term Investments	-0.72	-0.32	-0.4	-0.58	-0.74	-0.49	-0.27	-0.56	-0.59	0.26	-0.72	0.25	0.27	-0.6	-0.11	-0.46	0.05	-0.54	-0.45	-0.62	-0.34	-0.75	-0.5	0.83	0.66

Click cells to compare fundamentals

Lifecore Biomedical Account Relationship Matchups

Lifecore Biomedical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	541.3M	502.9M	295.2M	295.4M	273.7M	248.7M
Short Long Term Debt Total	221.1M	221.4M	153.2M	153.1M	130.4M	66.0M
Other Current Liab	19.0M	55.0M	16.9M	20.2M	15.5M	14.2M
Total Current Liabilities	164.4M	101.9M	79.2M	79.4M	38.9M	55.0M
Total Stockholder Equity	231.0M	202.8M	107.9M	108.1M	53.9M	51.2M
Property Plant And Equipment Net	200.0M	217.7M	200.4M	139.0M	151.0M	78.8M
Net Debt	220.8M	220.1M	151.5M	151.4M	121.9M	128.0M
Retained Earnings	71.2M	38.6M	(58.9M)	(58.7M)	(166.5M)	(158.2M)
Accounts Payable	51.6M	16.3M	15.8M	13.0M	16.3M	22.1M
Cash	1.1M	360K	1.3M	1.6M	8.5M	10.6M
Non Current Assets Total	386.1M	384.2M	354.6M	171.4M	172.9M	161.8M
Non Currrent Assets Other	(9.7M)	(25.3M)	(26.7M)	3.0M	3.8M	4.0M
Cash And Short Term Investments	1.1M	360K	1.3M	1.6M	8.5M	13.1M
Common Stock Shares Outstanding	29.2M	29.3M	29.5M	29.5M	36.7M	26.4M
Liabilities And Stockholders Equity	541.3M	502.9M	295.2M	295.4M	273.7M	248.7M
Non Current Liabilities Total	145.9M	198.3M	108.0M	107.9M	180.9M	190.0M
Inventory	66.3M	69.7M	66.8M	67.0M	40.0M	26.6M
Other Current Assets	14.2M	42.7M	7.1M	41.4M	1.4M	1.4M
Other Stockholder Equity	160.3M	162.6M	165.5M	167.4M	177.8M	121.9M
Total Liab	310.3M	300.1M	187.2M	187.3M	219.8M	110.9M
Total Current Assets	157.1M	148.3M	123.7M	124.0M	81.0M	86.2M
Short Term Debt	93.4M	30.6M	45.6M	142.5M	4.9M	4.7M
Net Receivables	76.2M	41.4M	48.2M	38.3M	31.2M	33.9M
Intangible Assets	45.2M	38.1M	36.1M	15.6M	4.2M	4.0M
Current Deferred Revenue	499K	352K	1.1M	919K	2.1M	1.3M
Good Will	54.5M	76.7M	69.4M	13.9M	16.0M	15.2M
Accumulated Other Comprehensive Income	64K	(2.8M)	(1.4M)	(586K)	(39.2M)	(37.3M)
Other Liab	14.6M	11.3M	422K	3.5M	3.1M	3.0M
Net Tangible Assets	123.6M	143.2M	78.5M	(19.9M)	(17.9M)	(17.0M)
Other Assets	2.2M	157.7M	3.0M	3.2M	19.7M	25.1M
Long Term Debt	101.4M	164.9M	97.6M	101.3M	120.5M	123.4M
Capital Lease Obligations	30.8M	27.5M	15.0M	11.0M	9.1M	12.9M
Net Invested Capital	421.4M	396.7M	246.1M	99.9M	132.6M	228.8M
Short Long Term Debt	89.0M	29M	40.6M	488K	773K	734.4K
Non Current Liabilities Other	4.6M	3.6M	190K	3.1M	5.1M	3.4M
Net Working Capital	(7.3M)	46.4M	44.5M	60.5M	42.2M	33.4M
Property Plant Equipment	217.7M	137.4M	139.0M	134.6M	121.1M	132.6M

Pair Trading with Lifecore Biomedical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lifecore Biomedical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifecore Biomedical will appreciate offsetting losses from the drop in the long position's value.

Moving against Lifecore Stock

0.79	JNJ	Johnson Johnson Sell-off Trend	Pair Corr
0.77	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.76	PFE	Pfizer Inc Fiscal Year End 4th of February 2025	Pair Corr
0.75	TCHH	Trustcash Holdings	Pair Corr
0.71	AGL	agilon health	Pair Corr

The ability to find closely correlated positions to Lifecore Biomedical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lifecore Biomedical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lifecore Biomedical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lifecore Biomedical to buy it.

The correlation of Lifecore Biomedical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lifecore Biomedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lifecore Biomedical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Lifecore Biomedical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Lifecore Stock Analysis

When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC